everyone, full-year XXXX. Thanks, joining us you quarter and for afternoon, thank Dan. for Good call for and fourth our corporate the update
a brief questions. our today's with for our of call programs an review begin will and before on We the opening update financials call up clinical
microRNA-targeted on indications. high have the need. disease for across candidates of we by continued and believe reported Looking clinical pipeline, candidates supports advancements been compelling includes made product candidates back ongoing the data to development across patients the stage development excited with which We unmet has date over indications product the these we our these for three several medical are XXXX, product
an fungoides, demonstrated with responses During XXXX, trial in of burden data that I mycosis tumor from or the skin form CTCL quality-of-life. T-cell in of and we Phase cutaneous most measured cobomarsen total durable lymphoma topline improvement by presented scoring common patients our as
addition, mSWAT XX% XX past Lymphoma with a over dosing. dose all of Assessment patients XX Tool skin dose In This I trial. or which to the days extended tolerated appeared after levels months is of of Annual January after severity or mSWAT treatment. periods showed data well or interim the evaluated we one as for ATLL on observed modified the time seen Weighted entire at CTCL this generally of presented of complete regards patient’s These from adult measurement improvements. T-cell improvement in be improvements first cobomarsen leukemia/lymphoma score, more and mSWAT body. and score Forum, disease data T-cell In CTCL, based Phase patient’s or as Severity a of at in early greatest XX were the scores to
patients least partial patients, trial eight for advance cobomarsen we is which Additionally, cobomarsen the our greater as data four in supported IV treating I five achieved the SOLAR We five at consecutive decision that SOLAR at and response partial score trial. also proof-of-concept or Phase primary receiving of least the patients Of of the partial will reduction, infusion The XX% those maintain is maintained achieved a II Phase response endpoint which clinical is four to a four to for that measure ORRX the months. known ability believe clinical months in for XXX-milligram the MF response. mSWAT into cobomarsen.
II in clinical of route the Phase reminder, the As is infusion administration SOLAR IV a used XXX-milligram and trial. dose being
sites. we the status of those believe XX focused high sites on are we onboarding In up worldwide, to enrolling including the terms of trial, will SOLAR be
team enrollment and to XXXX, patient than dosing to topline selection am move We due of physician pleased of sites the direct the our to in ongoing of and outreach, by we the time team. that outreach while our believe efforts on efforts initial had originally say positively with half of within initial originally remains been track site that communicate our to will second I impacted SOLAR in has frame anticipated. the patients begin expect ultimately believe longer process patient to we our with the XXXX. ahead clinical We of onboarding sites for XXXX early guided the and deliver trial be data
safety vorinostat per disease over SOLAR in overview, of discussions to for States. and the CTCL, response endpoint is in viscera SOLAR in on our the Progression-free the is quality-of-life a in we of no evidence progression objective treatment maintained endpoints efficacy months. endpoint the use the the approximately CTCL. secondary and with primary for to improvements. XX rate of expected group. the entire patients plan at with expect enroll will allow skin Based a primary disease the to least trial we to improvement trial XX% control from approval apply or as consecutive severity the defined in lymph greater four patient-reported The patient's of blood, or body a comparison in evaluate for is endpoint cobomarsen active achievement to patients as The trial outcomes monitor with the As United be us of SOLAR our an designed secondary nodes quick versus trial trial FDA, could cobomarsen that survival accelerated of additional
the in $X to invaluable the conducting milestones which is with As previously support, connection of achievement specified providing pleased the disclosed, in Society, trial including be are up with the we million Lymphoma upon funding, in SOLAR Leukemia and association trial. to
at in also on in Annual As I presented T-cell Lymphoma ATLL we mentioned Forum the earlier, data cobomarsen patients January. with new
cobomarsen eight a patients, cobomarsen lymphomatous these cutoff date. XX, stable to Of five have on patients months, while in remained ATLL the and with we three of XX XXXX the remission that treated XX, clinical with eight the of or total monotherapy still December as I improved, partial are treatment Phase December acute patients As of trial. and from been continuing in expanded were XXXX, ATLL had with
to Ki-XX, progression, treatments, patients ranges are and The on SAEs disease. In been to it this the after life poor severity, in this believe biomarkers associated important existing prognosis, poor are despite a devastating the addition patients. patients have for to of four trial with remember study shown are have with in improve XX months patients In marker infections, events with ATLL new monotherapy, cells We related drug reported Elevations disease with expectancy diagnosis. for there this had and previously in essential that which tumor to a including evidence we while the common indicative disease. survival have is patients decrease of on serious safety acute initial evidence to opportunistic in failed cobomarsen the on demonstrated been to regard to or of no typically adverse from none demonstrated patients no median patient extremely the of subsets of therapies patients disease disease these Ki-XX in circulating cell of proliferation. correlate ATLL in and other therapies seen outcomes
in cobomarsen subtype third Phase from data is presentation DLBCL, to States. three with Included diagnosed B-cell most with the January, B-cell we of in large data non-Hodgkin’s common our with in the of and DLBCL I patients lymphoma on treated presented diagnosed trial activated of cobomarsen. United non-Hodgkin lymphoma accounting the newly for of type the patients lymphoma which or Turning diffuse one to up
nodes X, and of remains on As had nodes a January one XXXX, after in seen measured stabilization lymph second in complete cobomarsen. of seven This weeks two one reduction lymph therapy. patient of patient
from immediate to Previously, relapsed month all treatments less after three The experimental received patients range cycles over than chemotherapy. with of from XX of these other XX other patients therapy two response. to lack Prior care diagnosis. discontinued patients for multiple standard after treatments to therapies of one due months had
the While sample are this with the patient. we reported responding small in a activity was pleased size,
to we these the chronic has continue DLBCL, to improve in evaluate as for quality-of-life will leukemia We patients it patients. cobomarsen the believe and potential lymphocytic
remlarsen. to Turning
We double-blinded safety, remlarsen II scars, trial the and second history tolerability the reduction of Phase XXXX. in keloid report This of in or hypertrophic of trial are is half expected keloid II remlarsen to a of randomized prevention currently is formation with in form assessing clinical of Phase that conducting a activity a persistent data for the subjects scarring.
of presence to statistical trial, on the up reduce which predisposed is injected trauma. The lesions are patients. with as We that power placebo. a months of remlarsen remlarsen expect relatively the XX-subject small healing. healthy trial sutured believe affecting keloid their appeared formation. In formation receive for will matching a control, this We tissue induced human volunteers to then build determine wound Phase after to subjects cohort, be small initially and scar increases trial serving without in absence XX opportunity to that Thus, exciting clinical patients up excisional own are deposition where individuals enroll this to of to with number cutaneous data of the fibrosis, or will consisting I observed in or the keloid wounds either an are
Turning to MRG-XXX.
with blood collaboration healing. has important been in Servier. vessel in which regulation an and of MRG-XXX to developing growth are of shown new is microRNA-XX, We the be MRG-XXX inhibitor
its support patients including trials additional two lacerations. better in use where oxygenation, that from clinical As the failure being of indications, potential evaluated growth blood new difficult-to-heal allow separate intended benefit a vessel trials multiple in reminder, including would could and conditions MRG-XXX other for and is heart burns increased I and to treatment Phase
these been of our steady data believe to and for stage three current planned clinical recently, candidates supports entered in call Officer, with strategy our turn several supporting to trials microRNA-based We have that product programs from the therapeutics announce today. need. and reported expect clinical review in made We clinical will Jason important XXXX. our to targeted the clinical now that, further three milestones. the Financial trials near-term of for earlier results an become stage financial microRNA-based that advancing class believe Leverone, ongoing evidence We for XXXX has data potential With presented I candidates. will We've progress we the in new the Jason? patients our over to provide therapies these Chief
